Natural History of Autoimmune Diabetes and Its Complications

Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
Overall Status
Terminated
CT.gov ID
NCT00896610
Collaborator
(none)
356
1
136.6
2.6

Study Details

Study Description

Brief Summary

Background:
  • Diabetes is a disease defined by abnormally high blood sugar (glucose) levels. Glucose is an essential source of energy for the body s cells, but insulin is required to move the glucose into the cells. Insulin is a hormone produced by the pancreas that allows glucose to enter cells.

  • In diabetes, the body is unable to supply enough insulin to meet its demands. The problem may be a low supply of insulin or a high demand for insulin. Someone who has been diagnosed with diabetes has lost much of their insulin-producing capacity. Clinical studies have shown that good control of blood sugar is essential to prevent diabetes complications like damage to the eyes, kidneys, nerves, and blood vessels.

Objectives:
  • To establish a relationship with several individuals with diabetes caused by the immune system attacking the body s insulin-producing cells in order to:

  • Explore why the immune system attacks insulin-producing cells.

  • Understand why some individuals develop diabetes-related complications and others do not.

  • Develop therapies to improve how patients can control their blood sugar levels.

  • Continue to follow subjects who have completed or are considering other NIH diabetes-related studies.

  • To develop improved tests for determining an individual s risk for developing diabetes and/or to accurately diagnose the exact type of diabetes.

Eligibility:
  • Individuals who have been diagnosed with or are at risk for developing diabetes.
Design:
  • Standard physical examination and clinical tests to determine if the patient has diabetes or to confirm a particular type of diabetes:

  • None of the treatment in this study is experimental.

  • Patients will receive a separate consent form for any special tests needed to learn more about their particular type of diabetes.

  • Patients may be asked to provide additional urine and blood samples for use in laboratory research about diabetes.

  • Researchers may offer medical treatment advice for diabetes, or explain how to improve patients diabetes management skills.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Individuals with known or suspected autoimmune mediated diabetes, or healthy individuals at risk for developing the disease, will be evaluated at the NIH Clinical Center. Studies will include characterizing the disease s clinical and laboratory features, observing the natural history of the disease and its complications, evaluating responses to standard treatments. Protocol enrollees may be asked to contribute blood and/or urine samples for immunological research studies, and/or for studies designed to find parameters that increase a subject s risk for diabetes and/or its associated complications.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    356 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Natural History of Autoimmune Diabetes and Its Complications
    Actual Study Start Date :
    May 13, 2009
    Actual Primary Completion Date :
    Sep 30, 2020
    Actual Study Completion Date :
    Sep 30, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Diabetes

    Individuals who have been diagnosed with or are at risk for developing diabetes

    Outcome Measures

    Primary Outcome Measures

    1. Blood glucose level [every 3 months]

      Blood glucose level within a range appropriate for the patient's condition.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    -INCLUSION CRITERIA:

    1. Clinical diagnosis of diabetes, either type 1 (T1D) or insulin-requiring type 2 (T2D),

    2. Healthy individuals who may be at risk for developing diabetes,

    3. Individuals with suspected immune mediated diabetes,

    4. Willingness of the patient or guardian to give informed consent and assent.

    EXCLUSION CRITERIA:
    1. Concomitant medical problems which would confound the interpretation studies of the autoimmune beta cell destructive process

    2. Concomitant medical, surgical, or other conditions for which adequate facilities or funds are not available to support their care at the NIH.

    3. Any other co-existing condition/circumstances that would make a subject unsuitable to participate in the study, as deemed by the investigators.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Investigators

    • Principal Investigator: Ranganath Muniyappa, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    ClinicalTrials.gov Identifier:
    NCT00896610
    Other Study ID Numbers:
    • 090140
    • 09-DK-0140
    First Posted:
    May 11, 2009
    Last Update Posted:
    Oct 8, 2020
    Last Verified:
    Oct 1, 2020
    Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 8, 2020